Prosecution Insights
Last updated: November 04, 2026
Application No. 17/679,940

FLUID DELIVERY DEVICES AND METHODS

Non-Final OA §103§112§DP
Filed
Feb 24, 2022
Priority
Jun 03, 2015 — provisional 62/170,216 +2 more
Examiner
STUART, COLIN W
Art Unit
3785
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Droplette Inc.
OA Round
3 (Non-Final)
58%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
514 granted / 887 resolved
-12.1% vs TC avg
Strong +55% interview lift
Without
With
+54.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
28 currently pending
Career history
922
Total Applications
across all art units

Statute-Specific Performance

§101
5.8%
-34.2% vs TC avg
§103
37.4%
-2.6% vs TC avg
§102
12.0%
-28.0% vs TC avg
§112
34.2%
-5.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 887 resolved cases

Office Action

§103 §112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This office action is in response to the request for continued examination filed 7/3/26 and the amendments filed 5/19/26 which are hereby entered. As directed by the amendment: claims 2, 6, 8, 12, 15, and 20 have been amended, claim 4 has been cancelled, and no claims have been added. As such, claims 2-3 and 5-22 are pending in the instant application. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 5/19/26 has been entered. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 11-12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 11, the language “the pump includes a fluid inlet port and a fluid outlet port” (line 1-2) is unclear as amended claim 2 already sets forth an inlet port and an outlet port of the pump and it is not known if Applicant is intending to set forth additional inlet and outlet ports or refer back to the previously set forth ports. Regarding claim 11, the language “the fluid inlet and outlet ports” (line 2) is unclear as per above, it is not known of Applicant has set forth additional inlet and outlet ports (additional to the ones set forth in amended claim 2) and if so which inlet/outlet ports this language is referring to. Regarding claim 12, the language “the fluid inlet and outlet ports” (line 2) is unclear as per above, it is not known of Applicant has set forth additional inlet and outlet ports (additional to the ones set forth in amended claim 2) and if so which inlet/outlet ports this language is referring to. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim(s) 2-3, 5-7, 9, 11, 13, 16, and 18-19 is/are rejected under 35 U.S.C. 103 as being unpatentable over Burt et al. (2013/0079733) in view of Ganan-Calvo (6,405,936). Regarding claim 2, Burt discloses a fluid delivery device (see abstract, Fig. 36-37, para. 0005, 0165 for example) which includes a housing (see Fig. 36-37, housing 170, para. 0164); a fluid vaporizer disposed within the housing and configured to receive fluid and produce an aerosol mist of liquid particles from the fluid (see Fig. 36-37, fluid vaporizer 20, para. 0165, 0113, 0005), and a pump configured to draw in the produced aerosol mist via an inlet port thereof (see annotated Fig. 37 below), and accelerate the aerosol mist produced by the vaporizer and eject the vaporized fluid via an outlet thereof (see Fig. 36-37, pump labeled below in annotated Fig. 37, which receives the fluid from vaporizer 20 and accelerates it to be ejected from the device via outlet 162 as shown). Burt is silent as to the ejected vaporized fluid having a Weber number that is equal to or greater than 1; however, Ganan-Calvo discloses an aerosol delivery device which ejects aerosol having a Weber number that is equal to or greater than 1 (see Ganan-Calvo col. 2 ln. 35-46 and col. 13 ln. 25-34). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the Burt device to eject vaporized liquid with a Weber number that is equal to or greater than 1, as taught by Ganan-Calvo, in order to provide a stable microjet of flow with desired monodisperse aerosol with high degree of uniformity in particle size (see Ganan-Calvo col. 2 ln. 35-46 and col. 13 ln. 25-34). PNG media_image1.png 445 776 media_image1.png Greyscale Regarding claim 3, the modified Burt device’s fluid vaporizer includes a piezoelectric transducer (see Burt para. 0020 for example). Regarding claim 5, the modified Burt device’s pump is configured to reduce a size of the liquid particles produced by the fluid vaporizer (the modified Burt device includes each structural and functional limitation that it would also reduce the size of the liquid particles). Regarding claim 6, the modified Burt device’s pump is configured to reduce a size on average of the liquid particles produced by the vaporizer by a factor of 10 (the modified Burt device includes each structural and functional limitation that it would also reduce the size of the liquid particles by a factor of 10). Regarding claim 7, the modified Burt device’s housing has a fluid-retaining reservoir and the vaporizer is configured to receive fluid from the reservoir (see Burt Fig. 37, reservoir 80, see para. 0165). Regarding claim 9, the modified Burt device’s housing has an outlet formed therein and positioned such that the vaporizer can eject the mist from the housing through the outlet (see Burt Fig. 37 housing 170 having an outlet which allows fluid to be ejected via 162). Regarding claim 11, the modified Burt device’s pump includes a fluid inlet port and fluid outlet port being positioned adjacent to the outlet in the housing (see Burt Fig. 37 and annotated Fig. 37 above showing pump inlet labeled and pump outlet at 162). Regarding claim 13, the modified Burt device further includes a cartridge removably matable to the housing and configured to deliver fluid to the housing (see Burt Fig. 37, removable cartridge 80, see para. 0028-0031). Regarding claim 16, the modified Burt device further includes a controller disposed on the housing and configured to alter a frequency of the vaporizer and at least one of pump speed or duration (see Burt para. 0024-0025, 0164-0165). Regarding claim 18, the modified Burt device is configured to eject a vaporized fluid having a Weber number that is in a range of 1 to 100 (see Ganan-Calvo col. 2 ln. 35-46 and col. 13 ln. 25-34). Regarding claim 19, the modified Burt device is configured to eject a vaporized fluid having a Weber number that is in a range of 10 to 50 (see Ganan-Calvo col. 2 ln. 35-46 and col. 13 ln. 25-34). Claim(s) 8 is/are rejected under 35 U.S.C. 103 as being unpatentable over Burt and Ganan-Calvo as applied to claim 2 above, and further in view of Srinivasan et al. (2004/0260234). Regarding claim 8, the modified Burt device is silent as to the vaporizer and pump being configured to generate mist that can pass into up to 1 cm of tissue when an outlet of the housing through which the aerosol passes is positioned about 1 cm away from the tissue; however, Srinivasan discloses a similar device which teaches this limitation (see Srinivasan para. 0005 and 0109). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the modified Burt device to generate mist to pass into up to 1 cm of tissue when positioned about 1 cm away, as taught by Srinivasan, in order to provide transdermal delivery of drugs to the patient (see Srinivasan para. 0005 and 0109). Claim(s) 14-15 is/are rejected under 35 U.S.C. 103 as being unpatentable over Burt and Ganan-Calvo as applied to claims 13 and 2 above, and further in view of Smith et al. (2003/0140921). Regarding claim 14, the modified Burt device is silent as to the cartridge including dosage or timing instructions to the device including pump speed and frequence of vibration of the vaporizer (see Burt para. 0024-0025, 0164-0165 which discloses control of operating parameters); however, Smith discloses a similar vaporizer device which includes a cartridge including dosage/timing instructions (see Smith Fig. 1 and 11, para. 0050, 0076-0078). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the modified Burt device’s cartridge to provide dosing/timing instructions, as taught by Smith, to provide proper control for delivery of the fluid held within the cartridge (Smith abstract, para. 0050, 0076-0078). Regarding claim 15, the modified Burt device discloses an activation switch electronically coupled to the vaporizer and pump to activate these elements (see Burt Fig. 36-37, control buttons/switches 163,163A, see para. 0164). Burt is silent as to the activation being according to dosage instructions of the cartridge (Burt para. 0024-0025, 0164-0165 which discloses control of operating parameters); however, Smith discloses a similar vaporizer device which includes a cartridge including dosage/timing instructions (see Smith Fig. 1 and 11, para. 0050, 0076-0078). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the modified Burt device’s cartridge to provide dosing/timing instructions, as taught by Smith, to provide proper control for delivery of the fluid held within the cartridge (Smith abstract, para. 0050, 0076-0078). Claim(s) 17 is/are rejected under 35 U.S.C. 103 as being unpatentable over Burt and Ganan-Calvo as applied to claim 2 above, and further in view of Riebman et al. (2016/0114112). Regarding claim 17, the modified Burt device is silent as to including a sensor disposed on the housing configured to determine a distance from the device to a skin of a patient (Burt para. 0028 disclosing various sensors such as proximity sensor); however, Riebman discloses a similar vaporizer device which includes a sensor configured to determine a distance of the device to skin of the patient (see Riebman para. 0089). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the modified Burt device to include a sensor to determine distance from the skin of the patient, as taught by Riebman, in order to ensure proper positioning of the device in relation to the patient. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 2, 5-6, 9-12, and 18-22 rejected on the ground of nonstatutory double patenting as being unpatentable over claims 21-23 of U.S. Patent No. 11,273,267. Although the claims at issue are not identical, they are not patentably distinct from each other because the patent claims include each structural and functional limitations as claimed (see claim 19 which discloses housing, fluid vaporizer, and pump as claimed with inlet and outlet ports, claim 21 disclosing the claimed Weber number and thus resultant fluid flow properties, individual non-coalescing droplets via inertia-dominated fluid regime) but also includes additional elements, such as the inlet and outlet configured to disrupt flow path of the aerosol mist, such that the patent claims are narrower versions of the instant claims. Instant claims 2, 5-6, 9-12, and 20 correspond to patent claim 21. Instant claims 18 and 21 correspond to patent claim 22. Instant claims 19 and 22 correspond to patent claim 23. Claims 3, 7, 13, and 16 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 21 of U.S. Patent No. 11,273,267 in view of Burt. Regarding instant claim 3, the patent claim 21 is silent as to the vaporizer including a piezoelectric transducer; however, Burt teaches this limitation (see Burt para. 0020 for example). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the patent claim 21 device’s vaporizer to be a piezoelectric transducer, as taught by Burt, as this would have been obvious substitution of one known element for another and one would expect the modified patent claim 21 device to perform equally as well. Regarding instant claim 7, the patent claim 21 is silent as to the housing has a fluid-retaining reservoir and the vaporizer is configured to receive fluid from the reservoir; however, Burt teaches this limitation (see Burt Fig. 37, reservoir 80, see para. 0165). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the patent claim 21 device to include a fluid-retaining reservoir, as taught by Burt, in order to provide the necessary structural elements to hold/contain a fluid to be vaporized and delivered to the patient. Regarding claim 13, the patent claim 21 is silent as to including a cartridge removably matable to the housing and configured to deliver fluid to the housing; however, Burt teaches this limitation (see Burt Fig. 37, removable cartridge 80, see para. 0028-0031). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the patent claim 21 device to include a removable cartridge, as taught by Burt, in order to provide the necessary structural elements to hold/contain a fluid to be vaporized and delivered to the patient. Regarding instant claim 16, the patent claim 21 is silent as to including a controller disposed on the housing and configured to alter a frequency of the vaporizer and at least one of pump speed or duration; however, Burt teaches this limitation (see Burt para. 0024-0025, 0164-0165). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the patent claim 21 device to include a controller, as taught by Burt, in order to provide necessary elements to provide controlled delivery of the vaporized mist. Claim 8 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 21 of U.S. Patent No. 11,273,267 in view of Srinivasan. Regarding instant claim 8, the modified patent claim 21 device is silent as to the vaporizer and pump being configured to generate mist that can pass into up to 1 cm of tissue when an outlet of the housing through which the aerosol passes is positioned about 1 cm away from the tissue; however, Srinivasan discloses a similar device which teaches this limitation (see Srinivasan para. 0005 and 0109). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the patent claim 21 device to generate mist to pass into up to 1 cm of tissue when positioned about 1 cm away, as taught by Srinivasan, in order to provide transdermal delivery of drugs to the patient (see Srinivasan para. 0005 and 0109). Claims 14-15 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 21 of U.S. Patent No. 11,273,267 in view of Burt and Smith. Regarding instant claim 14, the modified patent claim 21 device is silent as to the cartridge including dosage or timing instructions to the device including pump speed and frequence of vibration of the vaporizer (see Burt para. 0024-0025, 0164-0165 which discloses control of operating parameters); however, Smith discloses a similar vaporizer device which includes a cartridge including dosage/timing instructions (see Smith Fig. 1 and 11, para. 0050, 0076-0078). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the modified patent claim 21 device’s cartridge to provide dosing/timing instructions, as taught by Smith, to provide proper control for delivery of the fluid held within the cartridge (Smith abstract, para. 0050, 0076-0078). Regarding instant claim 15, the patent claim 21 device is silent as to an activation switch electronically coupled to the vaporizer and pump to activate these elements (see Burt Fig. 36-37, control buttons/switches 163,163A, see para. 0164) and is silent as to the activation being according to dosage instructions of the cartridge (Burt para. 0024-0025, 0164-0165 which discloses control of operating parameters); however, Smith discloses a similar vaporizer device which includes a cartridge including dosage/timing instructions (see Smith Fig. 1 and 11, para. 0050, 0076-0078). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the modified patent claim 21 device’s cartridge to provide dosing/timing instructions for activation via a switch, as taught by Smith and Burt, to provide proper control for delivery of the fluid held within the cartridge (Smith abstract, para. 0050, 0076-0078). Claim 17 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 21 of U.S. Patent No. 11,273,267 in view of Riebman. Regarding instant claim 17, the patent claim 21 device is silent as to including a sensor disposed on the housing configured to determine a distance from the device to a skin of a patient; however, Riebman discloses a similar vaporizer device which includes a sensor configured to determine a distance of the device to skin of the patient (see Riebman para. 0089). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the patent claim 21 device to include a sensor to determine distance from the skin of the patient, as taught by Riebman, in order to ensure proper positioning of the device in relation to the patient. Claims 2-3 and 5-22 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6, 8-11, and 16-21 of U.S. Patent No. 9,700,686 in view of Ganan-Calvo. Regarding instant claims 2 and 20, the patent claims include each structural and functional limitations as claimed (see claim 1 which discloses housing, fluid vaporizer, and pump as claimed with inlet and outlet ports; see patent claim 9), but is silent as to the ejected vaporized fluid having a Weber number that is equal to or greater than 1; however, Ganan-Calvo discloses an aerosol delivery device which ejects aerosol having a Weber number that is equal to or greater than 1 (see Ganan-Calvo col. 2 ln. 35-46 and col. 13 ln. 25-34). Thus it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the patent claimed device to eject vaporized liquid with a Weber number that is equal to or greater than 1, as taught by Ganan-Calvo, in order to provide a stable microjet of flow with desired monodisperse aerosol with high degree of uniformity in particle size (see Ganan-Calvo col. 2 ln. 35-46 and col. 13 ln. 25-34). Instant claims 2 and 18-19 correspond to patent claim 1. Instant claim 3 corresponds to patent claim 2. Instant claims 5-8 corresponds to patent claims 3-6, respectively. Instant claims 9-12 corresponds to patent claims 8-11, respectively. Instant claims 13-14 correspond to patent claims 16-17, respectively. Instant claims 15-17 corresponds to patent claims 19-21, respectively. Instant claims 20-22 correspond to patent claim 9. Allowable Subject Matter Claims 10 and 12 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph and non-statutory double patenting, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. Claims 20-22 would be allowable if rewritten or amended to overcome the rejection(s) under non-statutory double patenting, set forth in this Office action. Response to Arguments Applicant's arguments filed 5/19/26 have been fully considered but they are not persuasive. Applicant argues that claim 4 was previously not rejected for lack of obviousness over any prior art and claim 2 has been amended to incorporate the subject matter of claim 4 in full and is allowable (see pg. 6 of the response) is not well-taken. Claim 2 was not amended to incorporate the subject matter of claim 4 in full and rendered obvious over Burt in view of Ganan-Calvo as specified above. Applicant’s argument that the amended claims differ such that they are not subject to double patenting is not well-taken and the double patenting rejections are noted above. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to COLIN W STUART whose telephone number is (571)270-7490. The examiner can normally be reached M-F: 9-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Timothy Stanis can be reached at 571-272-5139. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /COLIN W STUART/ Primary Examiner, Art Unit 3785
Read full office action

Prosecution Timeline

Show 2 earlier events
Aug 18, 2025
Response Filed
Nov 19, 2025
Final Rejection mailed — §103, §112, §DP
May 19, 2026
Response after Non-Final Action
May 28, 2026
Response after Non-Final Action
Jun 26, 2026
Response after Non-Final Action
Jul 03, 2026
Request for Continued Examination
Sep 03, 2026
Response after Non-Final Action
Oct 02, 2026
Non-Final Rejection mailed — §103, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778837
VENTILATED VEHICLE SEAT WITH MASSAGE CAPABILITY
3y 10m to grant Granted Nov 03, 2026
Patent 12773509
FLOW-OPTIMIZED SUPPLY TO A BALLOON ELEMENT THAT SEALS DYNAMICALLY AND IN SYNC WITH ORGANS
4y 7m to grant Granted Oct 27, 2026
Patent 12773510
DEVICE FOR PERCUTANEOUS DILATIONAL TRACHEOTOMY
4y 2m to grant Granted Oct 27, 2026
Patent 12774066
BREATHABLE MASK, AND STRUCTURE OF ITS BODY
3y 7m to grant Granted Oct 27, 2026
Patent 12766273
DEVICES AND METHODS FOR DELIVERING A SUBSTANCE TO A BODY CAVITY
5y 3m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+54.6%)
3y 8m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 887 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month